Viking Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-359.64	-109.96	-85.9	-68.87	-54.99
Depreciation & Amortization	0.43	0.35	0.29	0.29	0.3
Other Amortization	0.06	0.09	0.09	0.06	0.02
Loss (Gain) From Sale of Investments	-9.34	-17.38	-8.2	1.22	3.91
Stock-Based Compensation	40.82	29.71	16.75	8.67	6.1
Other Operating Activities	0.01	0.04	0.04	0.04	0.01
Change in Accounts Payable	43.44	2.3	-1.02	7.09	-2.54
Change in Other Net Operating Assets	5.54	7.06	4.57	3.1	-0.38
Operating Cash Flow	-278.69	-87.79	-73.38	-48.4	-47.59
Investment in Securities	341.39	-553.37	-179.09	54.75	37.96
Investing Cash Flow	341.39	-553.37	-179.09	54.75	37.96
Issuance of Common Stock	76.44	654.57	278.5	12.51	7.63
Repurchase of Common Stock	-	-42.1	-7.12	-8.33	-0.71
Other Financing Activities	-	-	-	-0.02	-0.05
Financing Cash Flow	76.44	612.46	271.38	4.16	6.88
Foreign Exchange Rate Adjustments	-0.01	-0.15	-0.03	-0.26	-
Net Cash Flow	139.13	-28.84	18.88	10.26	-2.75
Levered Free Cash Flow	-160.22	-55.58	-42.36	-25.22	-32.16
Unlevered Free Cash Flow	-160.24	-55.61	-42.4	-25.24	-32.16
Change in Working Capital	48.98	9.36	3.55	10.19	-2.93

Source: S&P Global Market Intelligence. Standard template. Financial Sources.